▲ Peaking
Business
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte reports that its KRAS G12D-mutated pancreatic cancer treatment is inducing lasting tumor responses, placing the firm in a tight race with RevMed.